...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Combo with Enzalutamide in Phase 2 Metastatic Prostate Cancer Clinical Trial and with Pfizer’s PARPi, talazoparib, in Phase 1b/2 Triple Negative Breast Cancer Trial

Free
AGORACOM NEWS FLASH

BREAKING: Kontrol Receives Approval for Government Grant to Accelerate the Development of New COVID-19 Testing Technology

  • Received approval for an initial government grant of $50,000 from the National Research Council of Canada to accelerate its new Covid-19 testing technology, the Kontrol BioCloud® analyzer
  • Kontrol is developing a new technology designed to detect and alert for COVID-19, in real-time, through rapid on-site air sampling and detection of aerosol and droplet encapsulated viruses in indoor and outdoor environments
  • Kontrol has developed its initial prototype and has commenced lab testing of the detection chamber
  • The lab will spend the next 4 weeks testing the detection chamber and the applicable interactions with COVID-19

Kontrol corp logo final 1 1024x296

Hub On AGORACOM / Read Release

Message: Zenith Announces Annual and Special Meeting of Shareholders

Zenith Announces Annual and Special Meeting of Shareholders

https://www.zenithepigenetics.com/newsroom/news-releases?article=32

CALGARY, Alberta, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith”) announced today that its Annual and Special Meeting of Shareholders (the “Meeting”) is to be held Thursday, October 31, 2019 at Mount Royal University, Roderick Mah Centre for Continuous Learning – Ross Glen Hall (Room EC1040), 4825 Mount Royal Gate SW, Calgary, Alberta.

A Notice of Meeting and Management Information Circular, containing further details including matters to be considered at the Meeting and the start time, will be delivered to shareholders and filed on SEDAR at www.sedar.com on or about Monday, September 30, 2019.

Following the formal business of the Meeting, Donald McCaffrey, President and Chief Executive Officer, will provide a corporate update presentation.

About Zenith

Zenith Capital Corp. is a biotechnology investment company originally spun out of Resverlogix Corp. (TSX: RVX) in 2013. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical need. Zenith Epigenetics is developing various novel combinations of BET inhibitors with other targeted agents. The lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (“mCRPC”) and Triple Negative Breast Cancer.

For further information, please contact:

Investor Relations & Communications
Phone : 587-390-7865
Email : [email protected]
Website : www.zenithepigenetics.com

Share
New Message
Please login to post a reply